Diagnostic criteria and classification of mastocytosis: A consensus proposal

Leukemia Research

Volumn 25, Issue 7, 2001, Pages 603-625

  Valent, Peter ^a   Horny, Hans P ^b   Escribano, Luis ^c   Longley, B Jack ^d   Li, Chin Y ^e   Schwartz, Lawrence B ^f   Marone, Gianni ^g   Nuñez, Rosa ^c   Akin, Cem ^h   Sotlar, Karl ⁱ   Sperr, Wolfgang R ^a   Wolff, Klaus ^a   Brunning, Richard D ^j   Parwaresch, Reza M ^k   Austen, K Frank ^l   Lennert, Karl ^k   Metcalfe, Dean D ^h   Vardiman, James W ^m   Bennett, John M ⁿ  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF LÜBECK   (Germany)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e MAYO CLINIC   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF KIEL   (Germany)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m UNIVERSITY OF CHICAGO   (United States)

ⁿ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; BONE MARROW DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; LEUKOCYTE COUNT; MAST CELL LEUKEMIA; MASTOCYTOMA; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; SKIN DEFECT; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA;

EID: 0034983045     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00038-8     Document Type: Note

References (175)

1. Rare forms of urticaria
2. Beiträge zur kenntnis der granulierten bindegewebszellen und der eosino-philen leukozyten
3. Urticaria pigmentosa. A report of a case with autopsy
4. Mast cells and mast cell neoplasia: A review
5. Tissue mast cells in health and disease
6. Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital
7. Systemic mastocytosis
8. Significance of systemic mast cell disease with associated hematologic disorders
9. Blood findings in generalized mastocytosis: Evidence of frequent simultaneous occurrence of myeloproliferative disorders
10. Hematologic manifestation of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis
11. Mast cell leukemia: Report of a case and review of the literature
12. The natural course of urticaria pigmentosa
13. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
14. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
15. Indolent systemic mast cell disease in adults: Immunophenotypic characterization of bone marrow mast cells and its diagnostic implication
16. - cell population
17. Demonstration that human mast cells arise from a progenitor cell population that is CD34+, c-kit+, and expresses aminopeptidase N (CD13)
18. Mast cell typing: Demonstration of a distinct hemopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes
19. Immunoreactivity of normal and neoplastic human tissue mast cells with macrophage-associated antibodies, with special reference to the recently developed monoclonal antibody PG-M1
20. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis
21. Mast cell disease
22. Classification and diagnosis of mastocytosis: Current status
23. Biology, classification and treatment of human mastocytosis
24. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airline House, Virginia, November 1997
25. A proposed classification of mastocytosis incorporating molecular genetics
26. Recent advances in mastocytosis research
27. Shock and coagulation disorders in systemic mastocytosis
28. Anaphylaxis after hymenoptera sting in three patients with urticaria pigmentosa
29. Hyperchlorhydria and hyperhistaminemia in a patient with systemic mastocytosis
30. Gastrointestinal dysfunction in systemic mastocytosis. A prospective study
31. Gastrointestinal abnormalities and involvement in systemic mastocytosis
32. Heparin activity in systemic mastocytosis
33. Increased production of prostaglandin D2 in patients with systemic mastocytosis
34. Clinical and histopathological aspects of cutaneous mastocytosis
35. Mastocytosis with malabsorption, myelofibrosis, and massive ascites
36. A fatal case of portal hypertension complicating systemic mastocytosis in an adolescent
37. Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases
38. Variceal bleeding, hypersplenism, and systemic mastocytosis. Pathophysiology and management
39. Systemic mastocytosis: A rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis - Report of four cases
40. Functional asplenia in malignant mastocytosis
41. Pathologic fracture in systemic mastocytosis. Radiographic spectrum and review of the literature
42. Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures
43. Patterns of skeletal scintigraphy and their relationship to plasma and urinary histamine levels in systemic mastocytosis
44. Radiological features of systemic mast cell disease
45. Systemic mastocytosis: CT and US features of abdominal manifestations
46. Diagnosis of mastocytosis: Value of cytochemistry and immunohistochemistry
47. Bone marrow findings in systemic mastocytosis
48. Diagnosis of mastocytosis: General histopathological aspects, morphological criteria, and immunohistochemical findings
49. Systemic mastocytosis: Extracutaneous manifestations
50. Systemic mast cell disease (mastocytosis). General aspects and histopathologic diagnosis
51. Lymph node findings in generalized mastocytosis
52. Spleen findings in generalized mastocytosis. A clinicopathologic study
53. Liver findings in generalized mastocytosis. A clinicopathologic study
54. The liver, spleen, and lymph nodes in mastocytosis
55. Pathology of the lymph node and spleen in systemic mast cell disease
56. Different patterns of spleen involvement in systemic and malignant mastocytosis. A histopathological and immunohistochemical study of three cases
57. Interstitial cystitis and bladder mastocytosis in a woman with chronic urticaria
58. Urticaria pigmentosa: A clinical, hematopathologic, and serologic study of 30 adults
59. Bone marrow findings in adult patients with urticaria pigmentosa
60. Systemic mast cell disease: A clinical and hematopathologic study of 26 cases
61. Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: A histological and immunohistological study
62. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozym, and CD20 antibodies
63. Diagnostic utility of staining for tryptase in patients with mastocytosis
64. Expression of the c-kit gene product in normal and neoplastic mast cells but not in neoplastic basophil/mast cell precursors from chronic myelogenous leukaemia
65. Immunoreactivity of normal and neoplastic human tissue mast cells
66. Use of monoclonal antibody KP1 for identifying normal and neoplastic human mast cells
67. A case of malignant mastocytosis with circulating mast cell precursors: Biologic and phenotypic characterization of the malignant clone
68. Bone marrow mastocytosis associated with an undifferentiated extramedullary tumor of hemopoietic origin
69. Identification of normal and neoplastic mast cells by immunohistochemical demonstration of tryptase in paraffin sections
70. Morphologie und differentialdiagnose der akuten myelogenen leukämien
71. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemia blast crisis
72. Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells
73. Clinical and biologic diversity of leukemias occuring in patients with mastocytosis
74. Concomitant bone changes in urticaria pigmentosa
75. Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis
76. Proposals for the classification of the myelodysplastic syndromes
77. The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group
78. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group
79. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
80. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0)
81. Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis
82. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis
83. Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis
84. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis
85. The potential clinical utility of serum alpha-protryptase levels
86. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders
87. Evaluation of human peripheral blood leukocytes for mast cell tryptase
88. Recombinant human stem cell factor stimulates differentiation of human mast cells from dispersed fetal liver cells
89. Development of human mast cells from umbilical cord blood cells by recombinant human and murine stem cell factor, c-kit ligand
90. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor (SCF)/kit ligand (KL) in long term culture
91. Mast cell lineage development and phenotypic regulation
92. Expression of c-kit antigen (c-kit proto-oncogen product) by normal human bone marrow cells
93. IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells
94. v mice and their increase by bone marrow transplantation
95. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product
96. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
97. c-kit mutation in a population of patients with mastocytosis
98. Why should the presence of specific c-kit mutations be used as a basis of classification of mastocytosis?
99. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis
100. Systemic mastocytosis associated with acute myeloid leukaemia: Report of two cases and detection of the c-kit mutation Asp-816 to Val
101. c-kit mutations and mast cell disorders. A model of activating mutations of growth factor receptors
102. Identification of activating c-kit mutations in adult-, but not childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behaviour
103. c-kit and c-kit mutations in mastocytosis and other hematological diseases
104. A new c-kit mutation in a case of aggressive mast cell disease
105. A case of smouldering mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val
106. Detection of c-kit mutation Asp-816-Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukemia
107. Sequential immunophenotypic analysis of mast cells in a case of systemic mastocytosis evolving to a mast cell leukemia
108. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration
109. Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathologic bone marrow samples
110. Expression of lymphoid-associated antigens in mast cells: Report of a case of systemic mast cell disease
111. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis
112. Mast cell differentiation antigens: Expression in normal and malignant cells and use for diagnostic purposes
113. Mast cell leukemia: Evidence for bone marrow origin of the pathologic clone
114. Cell surface structures on human basophils and mast cells: Biochemical and functional characterization
115. L
116. Preleukemia and urticaria pigmentosa followed by acute myelomonoblastic leukemia
117. Mastocytosis and co-existing Non Hodgkin's lymphoma and myeloproliferative disorders
118. Systemic mastocytosis associated with chronic myelomonocytic leukemia: Clinical features and response to interferon alfa therapy
119. Concurrent acute myeloid leukemia and systemic mastocytosis
120. Systemic mast cell disease associated with the hypereosinophilic syndrome
121. Systemic mastocytosis in a patient with polycythemia vera treated with radioactive phosphorus
122. Primary thrombocythemia associated with systemic mastocytosis: A report of five cases
123. Acute nonlymphocytic leukemia in systemic mastocytosis with biclonal gammopathy
124. Generalized cutaneous mastocytosis and acute myelogenous leukemia
125. Lymphadenopathic mastocytosis with eosinophilia and biclonal gammopathy
126. Mast cell disease followed by leukemia with clonal evolution
127. Systemic mast cell disease associated with hairy cell leukemia
128. A case of bone marrow mastocytosis associated with multiple myeloma
129. Slowly progressive systemic mastocytosis with high mast cell burden and no evidence of a non-mast cell hematologic disorder: An example of a smoldering case?
130. Mastocytosis: Molecular mechanisms and clinical disease heterogeneity
131. Telangiectasia macularis eruptiva perstans with mastocytosis
132. Telangiectasia macularis eruptiva perstans
133. Dermal mast cells in mastocytosis: Fixation, distribution, and quantitation
134. Mast cells in cutaneous mastocytosis: Accumulation of the MCTC type
135. Two human mast cell subsets with distinct neutral protease composition
136. Diffuse cutaneous mastocytosis with multiple cutaneous mastocytomas. Report of a case with clinical, histopathological and ultrastructural aspects
137. Systemic mastocytosis with extensive large cutaneous mastocytomas: Surgical management
138. Erythrodermic mastocytosis
139. Diffuse cutaneous mastocytosis
140. Bullous mastocytosis
141. Solitary mastocytoma of the eyelid. A case report with special reference to the immunocytology of human tissue mast cells, and a review of the literature
142. Benign and malignant mast cell proliferations. Diagnosis and separation using a pH-dependent toluidine blue stain in tissue sections
143. Human bone marrow mast cells in systemic mast cell disease. Ultrastructure and evaluation of fixation and staining techniques
144. Lymphadenopathic mastocytosis with eosinophilia
145. Zur pathologischen anatomie der mastozytosen
146. Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations
147. Tissue mast cell leukemia
148. Cytobiological and clinical aspects of tissue mast cell leukemia
149. Malignant mastocytosis with circulating mast cells
150. Mast cell sarcoma of the larynx
151. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon
152. A case of mastocytoma with leukemic manifestation of its immature form in the terminal stage
153. Solitary mast cell 'tumor' of the lung, its place in the spectrum of mast cell disease
154. Solitary mast cell granuloma (histiocytoma) of the lung. A histologic, tissue culture and time-lapse cinematographic study
155. Solitary mast cell tumor of the lung
156. A solitary manifestation of mastocytosis in the head and neck
157. The treatment of mastocytosis
158. Treatment of mastocytosis: Pharmacologic basis and current concepts
159. Intervention with epinephrine in hypotension associated with mastocytosis
160. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes
161. A case of systemic mastocytosis; therapeutic efficacy of ketotifen
162. Cromolyn sodium in the management of systemic mastocytosis
163. Oral disodium cromoglycate in the treatment of systemic mastocytosis
164. Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis
165. Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa
166. Response to interferon alpha-2b in a patient with systemic mastocytosis
167. Response of severe systemic mastocytosis to interferon alpha
168. Long term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia
169. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b
170. Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2B
171. Treatment of three patients with systemic mastocytosis with interferon alpha-2b
172. Hematologic aspects of mastocytosis. II. management of hematologic disorders in association with systemic mast cell disease
173. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome
174. Splenectomy in the management of systemic mast cell disease